Neurocrine Biosciences Deal History & Licensing Activity
Neurocrine Biosciences is a large biotech headquartered in US. Over the past three years, Neurocrine Biosciences has been involved in 9 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 22 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
4
Active Trials
22
Top Modality
Small Molecules
Focus Area
CNS Disorders
Neurocrine Biosciences Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Neurocrine Biosciences in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Vykas XR (DCCR) | Neurocrine | Small Molecules | Unknown | acquisition | Apr 2026 |
| Vykat | Soleno | Small Molecules | Unknown | acquisition | Apr 2026 |
| Vykat XR | Soleno Therapeutics | Small Molecules | Unknown | acquisition | Apr 2026 |
Neurocrine Biosciences Pipeline Focus
Therapeutic areas and modalities where Neurocrine Biosciences is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Neurocrine Biosciences Strategic Signals
Key indicators of Neurocrine Biosciences's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Neurocrine Biosciences Clinical Pipeline
Neurocrine Biosciences has 22 active clinical trials across 3 development phases.
1
Phase 4
7
Phase 2
14
Phase 3
See How Your Asset Matches Neurocrine Biosciences's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Neurocrine Biosciences Licensing & Deal Activity
Neurocrine Biosciences is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 9 deals over the past three years, Neurocrine Biosciences ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Neurocrine Biosciences include CNS Disorders (14 deals and trials), Mega Deals (8 deals and trials), Rare Disease (2 deals and trials), and Neurology (2 deals and trials). In terms of modality, Neurocrine Biosciences has shown particular interest in small molecules, other, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Neurocrine Biosciences and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Neurocrine Biosciences's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.